Schwermer M, Dreesmann S, Eggert A, Althoff K, Steenpass L, Schramm A, et al. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines. Clin Exp Ophthalmol. 2017;45:288-296 pubmed publisher

Harashima N, Minami T, Uemura H, Harada M. Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system. Mol Cancer. 2014;13:217 pubmed publisher

Busch M, Klein S, Große Kreul J, Scheiner O, Metz K, Stephan H, et al. p53, miR-34a and EMP1-Newly Identified Targets of TFF3 Signaling in Y79 Retinoblastoma Cells. Int J Mol Sci. 2019;20: pubmed publisher

Busch M, Große Kreul J, Wirtz J, Beier M, Stephan H, Royer Pokora B, et al. Reduction of the tumorigenic potential of human retinoblastoma cell lines by TFF1 overexpression involves p53/caspase signaling and miR-18a regulation. Int J Cancer. 2017;141:549-560 pubmed publisher

Farmaki E, Mkrtchian S, Papazian I, Papavassiliou A, Kiaris H. ERp29 regulates response to doxorubicin by a PERK-mediated mechanism. Biochim Biophys Acta. 2011;1813:1165-71 pubmed publisher

Cabello C, Lamore S, Bair W, Davis A, Azimian S, Wondrak G. DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma. Free Radic Res. 2011;45:276-92 pubmed publisher

Kuijk E, van Mil A, Brinkhof B, Penning L, Colenbrander B, Roelen B. PTEN and TRP53 independently suppress Nanog expression in spermatogonial stem cells. Stem Cells Dev. 2010;19:979-88 pubmed publisher